ABMA

ABMA is a broad-spectrum inhibitor of intracellular toxins and pathogens. ABMA efficiently protects cells against various toxins and pathogens including viruses, intracellular bacteria and parasite. ABMA selectively acts at host cell late endosomes rather than targeting toxin or pathogen itself. ABMA has broad-spectrum anti-infection activity^[1][2]. IC50 & Target: Intracellular bacteria^[1]
Viruses^[1]
Parasite^[1]
In Vitro: ABMA protects cells against four bacterial toxins (Corynebacterium diphtheriae (DT; EC₅₀ of 62.9 μM), Bacillus anthracis (LT), Clostridium difficile toxin B (TcdB; EC₅₀ of 73.3 µM), Clostridium sordellii lethal toxin (TcsL; EC₅₀ of 86.7 μM)), three viruses (Ebola (EC₅₀ of 3.3 µM), rabies (EC₅₀ of 19.4 µM), dengue-4 virus ( EC₅₀ of 8.2 µM)), two species of Chlamydiales intracellular bacteria (Simkania negevensis and Chlamydia trachomatis), and the parasite Leishmania infantum (EC₅₀ of 7.1 µM) at micromolar level^[1].
In A549 cells, ABMA treatment induces a decrease in ricin cytotoxicity with an EC₅₀ of 3.8 µM, and a protection factor (R) at 30 µM ranging from 5 to 10. ABMA retained almost 100% of its biological activity against ricin-induced cytotoxicity up to six days^[1]. In Vivo: ABMA (2-200 mg/kg; intraperitoneal injection; female BALB/c mice) treatment protects mice from nasal instillation of an LD₉₀ of ricin^[1].